Abbott Laboratories ABT faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants' questions asked during the ...

On Wednesday, Abbott Laboratories (NYSE ... Organic growth, excluding COVID-19 testing-related sales was 10.1%. Adjusted diluted earnings per share were $1.34, in line with the analyst estimates ...

A high throughput, highly automated test system for blood screening ... and documenting for every run. ABBOTT PRISM is designed to increase lab efficiency. It reduces manual steps and checks ...

His fears were that Abbott (NYSE:ABT) might pull the product entirely rather than risk further lawsuits—just like Johnson & ...

The outlook and technical action suggest Abbott Laboratories (NYSE ... in below consensus partly because of weakness in COVID-19 testing, but organic growth is double-digit, and all segments ...

Many Abbott Laboratories ( NYSE:ABT ) insiders ditched their stock over the past year, which may be of interest to ...

Worldwide COVID-19 testing sales were $176 million in the ... 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%. Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05 ...

Welcome to Abbott’s Fourth Quarter ... for our portfolio of respiratory disease tests used to help diagnose influenza, strep throat and RSV. In Core Laboratory Diagnostics, growth of 4% was ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion. Organic sales growth for the underlying base business ...